Trial Profile

Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sasineprocel (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man
Acronyms ASPERO; ASPIRO
Sponsors Aspen Neuroscience

Most Recent Events

30 Jun 2026 According to Aspen Neuroscience media release, the company announced that sasineprocel for the treatment of Parkinson's Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). The RMAT designation for sasineprocel is based on results from the ongoing Phase 1/2a ASPIRO trial.
30 Jun 2026 According to an Aspen Neuroscience media release, dosing in Cohort 3 and Cohort 4 of Phase I/IIa ASPIRO clinical trial has been completed.
14 May 2026 Planned primary completion date changed from 30 Oct 2025 to 30 Mar 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com